Disease Overview
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| BISANTRENE | ↓ inhibits | Mechanistic | DGIdb | |
| ATENOLOL | ? unclear | Mechanistic | DGIdb | |
| INTERFERON ALFA-2B | ? unclear | Mechanistic | DGIdb | |
| PEGINTERFERON ALFA-2A | ? unclear | Mechanistic | DGIdb | |
| AZATHIOPRINE | ? unclear | Mechanistic | DGIdb | |
| RIBAVIRIN | ? unclear | Mechanistic | DGIdb | |
| MERCAPTOPURINE | ? unclear | Mechanistic | DGIdb | |
| HYDROCHLOROTHIAZIDE | ? unclear | Mechanistic | DGIdb | |
| ROXADUSTAT | ↓ inhibits | Mechanistic | 9800.0 nM (IC50) | ChEMBL |
| CHEMBL2338328 | ↓ inhibits | Mechanistic | 84000.0 nM (IC50) | ChEMBL |
| CHEMBL485023 | ↓ inhibits | Mechanistic | 60000.0 nM (IC50) | ChEMBL |
| CHEMBL2338327 | ↓ inhibits | Mechanistic | 38000.0 nM (IC50) | ChEMBL |
| CHEMBL426560 | ↓ inhibits | Mechanistic | 2800.0 nM (IC50) | ChEMBL |
| CHEMBL2338326 | ↓ inhibits | Mechanistic | 43000.0 nM (IC50) | ChEMBL |
| CHEMBL2338325 | ↓ inhibits | Mechanistic | 96000.0 nM (IC50) | ChEMBL |
| CHEMBL2030875 | ↓ inhibits | Mechanistic | 92000.0 nM (IC50) | ChEMBL |
| CHEMBL1256568 | ↓ inhibits | Mechanistic | 15000.0 nM (IC50) | ChEMBL |
| CHEMBL2338323 | ↓ inhibits | Mechanistic | 18000.0 nM (IC50) | ChEMBL |
| CHEMBL2338322 | ↓ inhibits | Mechanistic | 23000.0 nM (IC50) | ChEMBL |
| CHEMBL1230640 | ↓ inhibits | Mechanistic | 3300.0 nM (IC50) | ChEMBL |
| BROMAMINIC ACID | ↓ inhibits | Mechanistic | 11000.0 nM (IC50) | ChEMBL |
| CHEMBL2338321 | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL316034 | ↓ inhibits | Mechanistic | 8300.0 nM (IC50) | ChEMBL |
| N-OXALYLGLYCINE | ↓ inhibits | Mechanistic | 44000.0 nM (IC50) | ChEMBL |
| CHEMBL3613953 | ↓ inhibits | Mechanistic | 13000.0 nM (Kd) | ChEMBL |
| CHEMBL4563024 | ↓ inhibits | Mechanistic | 700.0 nM (IC50) | ChEMBL |
| CHEMBL4559749 | ↓ inhibits | Mechanistic | 7600.0 nM (IC50) | ChEMBL |
| CHEMBL4470475 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4521076 | ↓ inhibits | Mechanistic | 4600.0 nM (IC50) | ChEMBL |
| CHEMBL4576909 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4435677 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4517902 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4471543 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4572939 | ↓ inhibits | Mechanistic | 60.0 nM (IC50) | ChEMBL |
| CHEMBL4563561 | ↓ inhibits | Mechanistic | 1140.0 nM (IC50) | ChEMBL |
| CHEMBL4460597 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4474254 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4453402 | ↓ inhibits | Mechanistic | 30000.0 nM (IC50) | ChEMBL |
| CHEMBL4567838 | ↓ inhibits | Mechanistic | 1600.0 nM (IC50) | ChEMBL |
| CHEMBL4532629 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
Showing top 40 of 166 agents ranked by evidence tier.
GIPR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| TIRZEPATIDE | ↑ activates | Mechanistic | 0.03 nM (EC50) | DGIdb |
| COMPOUND 15A [PMID: 36642961] | ↓ inhibits | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL198387 | ↓ inhibits | Mechanistic | 430.0 nM (IC50) | ChEMBL |
| CHEMBL234087 | ↓ inhibits | Mechanistic | 132.0 nM (IC50) | ChEMBL |
| CHEMBL411832 | ↓ inhibits | Mechanistic | 117.0 nM (IC50) | ChEMBL |
| CHEMBL395759 | ↓ inhibits | Mechanistic | 217.0 nM (IC50) | ChEMBL |
| CHEMBL411831 | ↓ inhibits | Mechanistic | 178.0 nM (IC50) | ChEMBL |
| CHEMBL232241 | ↓ inhibits | Mechanistic | 171.0 nM (IC50) | ChEMBL |
| CHEMBL232239 | ↓ inhibits | Mechanistic | 435.0 nM (IC50) | ChEMBL |
| CHEMBL398180 | ↓ inhibits | Mechanistic | 603.0 nM (IC50) | ChEMBL |
| CHEMBL396215 | ↓ inhibits | Mechanistic | 296.0 nM (IC50) | ChEMBL |
| CHEMBL407028 | ↓ inhibits | Mechanistic | 4256.0 nM (IC50) | ChEMBL |
| CHEMBL411833 | ↓ inhibits | Mechanistic | 2023.0 nM (IC50) | ChEMBL |
| CHEMBL232448 | ↓ inhibits | Mechanistic | 3525.0 nM (IC50) | ChEMBL |
| CHEMBL430163 | ↓ inhibits | Mechanistic | 1279.0 nM (IC50) | ChEMBL |
| CHEMBL232037 | ↓ inhibits | Mechanistic | 610.0 nM (IC50) | ChEMBL |
| CHEMBL232242 | ↓ inhibits | Mechanistic | 118.0 nM (IC50) | ChEMBL |
| CHEMBL232224 | ↓ inhibits | Mechanistic | 286.0 nM (IC50) | ChEMBL |
| CHEMBL198736 | ↓ inhibits | Mechanistic | 28.3 nM (IC50) | ChEMBL |
| CHEMBL452451 | ↓ inhibits | Mechanistic | 497.0 nM (IC50) | ChEMBL |
| CHEMBL528775 | ↓ inhibits | Mechanistic | 411.0 nM (IC50) | ChEMBL |
| CHEMBL447684 | ↓ inhibits | Mechanistic | 277.0 nM (IC50) | ChEMBL |
| CHEMBL455214 | ↓ inhibits | Mechanistic | 83.0 nM (IC50) | ChEMBL |
| CHEMBL487668 | ↓ inhibits | Mechanistic | 93.0 nM (IC50) | ChEMBL |
| CHEMBL447742 | ↓ inhibits | Mechanistic | 74.0 nM (IC50) | ChEMBL |
| CHEMBL504245 | ↓ inhibits | Mechanistic | 198.0 nM (IC50) | ChEMBL |
| CHEMBL453457 | ↓ inhibits | Mechanistic | 12.0 nM (IC50) | ChEMBL |
| CHEMBL520893 | ↓ inhibits | Mechanistic | 406.0 nM (IC50) | ChEMBL |
| CHEMBL487662 | ↓ inhibits | Mechanistic | 1392.0 nM (IC50) | ChEMBL |
| CHEMBL486651 | ↓ inhibits | Mechanistic | 98.0 nM (IC50) | ChEMBL |
| CHEMBL456738 | ↓ inhibits | Mechanistic | 145.0 nM (IC50) | ChEMBL |
| CHEMBL509710 | ↓ inhibits | Mechanistic | 279.0 nM (IC50) | ChEMBL |
| CHEMBL445532 | ↓ inhibits | Mechanistic | 380.0 nM (IC50) | ChEMBL |
| CHEMBL452311 | ↓ inhibits | Mechanistic | 216.0 nM (IC50) | ChEMBL |
| CHEMBL452067 | ↓ inhibits | Mechanistic | 220.0 nM (IC50) | ChEMBL |
| CHEMBL452310 | ↓ inhibits | Mechanistic | 3020.0 nM (IC50) | ChEMBL |
| CHEMBL504156 | ↓ inhibits | Mechanistic | 373.0 nM (IC50) | ChEMBL |
| CHEMBL499160 | ↓ inhibits | Mechanistic | 87.0 nM (IC50) | ChEMBL |
| CHEMBL375167 | ↓ inhibits | Mechanistic | 93.0 nM (IC50) | ChEMBL |
Showing top 40 of 187 agents ranked by evidence tier.
GLP1R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| CHEMBL:CHEMBL607309 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL585444 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1327172 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1224483 | ? unclear | Mechanistic | DGIdb | |
| CGP13501 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580340 | ? unclear | Mechanistic | DGIdb | |
| EFPEGLENATIDE | ↑ activates | Mechanistic | DGIdb | |
| LIRAGLUTIDE | ? unclear | Mechanistic | DGIdb | |
| DULOXETINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL597251 | ? unclear | Mechanistic | DGIdb | |
| ANGUSTIBALIN | ? unclear | Mechanistic | DGIdb | |
| DULAGLUTIDE | ↑ activates | Mechanistic | DGIdb | |
| EXENATIDE | ↑ activates | Mechanistic | 0.66 nM (IC50) | DGIdb |
| MOFEBUTAZONE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL532412 | ? unclear | Mechanistic | DGIdb | |
| NORTRIPTYLINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL533602 | ? unclear | Mechanistic | DGIdb | |
| PEGSEBRENATIDE | ↑ activates | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL317115 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1549738 | ? unclear | Mechanistic | DGIdb | |
| CYCLOASPEPTIDE A | ? unclear | Mechanistic | DGIdb | |
| SCOULERINE | ? unclear | Mechanistic | DGIdb | |
| KEPONE | ? unclear | Mechanistic | DGIdb | |
| PEGAPAMODUTIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL603154 | ? unclear | Mechanistic | DGIdb | |
| ETOPOSIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL405914 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1308346 | ? unclear | Mechanistic | DGIdb | |
| FIDUXOSIN HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CLOZAPINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578515 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1439833 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL601351 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580727 | ? unclear | Mechanistic | DGIdb | |
| AMORFRUTIN A | ? unclear | Mechanistic | DGIdb | |
| PROPIONYLPROMAZINE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL588038 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL1420370 | ? unclear | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL580207 | ? unclear | Mechanistic | DGIdb |
Showing top 40 of 294 agents ranked by evidence tier.
LEPR
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| MIBAVADEMAB | ↑ activates | Mechanistic | DGIdb | |
| SIMVASTATIN | ? unclear | Mechanistic | DGIdb | |
| VALPROIC ACID | ? unclear | Mechanistic | DGIdb | |
| METRELEPTIN | ↑ activates | Mechanistic | DGIdb | |
| ATORVASTATIN CALCIUM TRIHYDRATE | ? unclear | Mechanistic | DGIdb | |
| SETMELANOTIDE | ? unclear | Mechanistic | DGIdb |
MC4R
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| SETMELANOTIDE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| AMISULPRIDE | ? unclear | Mechanistic | DGIdb | |
| PF-00446687 | ↑ activates | Mechanistic | DGIdb | |
| CHLORHEXIDINE GLUCONATE | ? unclear | Mechanistic | DGIdb | |
| OLANZAPINE | ? unclear | Mechanistic | DGIdb | |
| QUETIAPINE FUMARATE | ? unclear | Mechanistic | DGIdb | |
| PMX53 | ? unclear | Mechanistic | DGIdb | |
| AMLINTIDE | ? unclear | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| SETMELANOTIDE | ↑ activates | Mechanistic | DGIdb | |
| ZIPRASIDONE | ? unclear | Mechanistic | DGIdb | |
| SORAFENIB | ? unclear | Mechanistic | DGIdb | |
| PALIPERIDONE | ? unclear | Mechanistic | DGIdb | |
| BREMELANOTIDE ACETATE | ↑ activates | Mechanistic | DGIdb | |
| ARIPIPRAZOLE LAUROXIL | ? unclear | Mechanistic | DGIdb | |
| METHYLNALTREXONE | ? unclear | Mechanistic | DGIdb | |
| BREMELANOTIDE | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL578944 | ? unclear | Mechanistic | DGIdb | |
| TREBANANIB | ? unclear | Mechanistic | DGIdb | |
| CLOZAPINE | ? unclear | Mechanistic | DGIdb | |
| CHEMBL415341 | ↑ activates | Mechanistic | 9.0 nM (EC50) | ChEMBL |
| CHEMBL437822 | ↑ activates | Mechanistic | 7.0 nM (EC50) | ChEMBL |
| CHEMBL24892 | ↑ activates | Mechanistic | 0.9 nM (EC50) | ChEMBL |
| CHEMBL438286 | ↑ activates | Mechanistic | 15.0 nM (EC50) | ChEMBL |
| CHEMBL412174 | ↑ activates | Mechanistic | 10.0 nM (EC50) | ChEMBL |
| CHEMBL264337 | ↑ activates | Mechanistic | 7.0 nM (EC50) | ChEMBL |
| CHEMBL439361 | ↑ activates | Mechanistic | 35.0 nM (EC50) | ChEMBL |
| CHEMBL2371902 | ↑ activates | Mechanistic | 3.0 nM (EC50) | ChEMBL |
| CHEMBL2371888 | ↑ activates | Mechanistic | 25.0 nM (EC50) | ChEMBL |
| CHEMBL3037885 | ↑ activates | Mechanistic | 0.3 nM (EC50) | ChEMBL |
| CHEMBL410148 | ↑ activates | Mechanistic | 2.0 nM (EC50) | ChEMBL |
| CHEMBL2371880 | ↑ activates | Mechanistic | 5.0 nM (EC50) | ChEMBL |
| CHEMBL2371903 | ↑ activates | Mechanistic | 2.0 nM (EC50) | ChEMBL |
| CHEMBL409786 | ↑ activates | Mechanistic | 6.0 nM (EC50) | ChEMBL |
| CHEMBL216474 | ↑ activates | Mechanistic | 37.0 nM (EC50) | ChEMBL |
| CHEMBL406636 | ↑ activates | Mechanistic | 176.0 nM (EC50) | ChEMBL |
| CHEMBL2371913 | ↑ activates | Mechanistic | 65.0 nM (EC50) | ChEMBL |
| CHEMBL262437 | ↑ activates | Mechanistic | 33.0 nM (EC50) | ChEMBL |
| CHEMBL386871 | ↑ activates | Mechanistic | 45.0 nM (EC50) | ChEMBL |
| CHEMBL384036 | ↑ activates | Mechanistic | 105.0 nM (EC50) | ChEMBL |
Showing top 40 of 143 agents ranked by evidence tier.
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| HALOPERIDOL DECANOATE | ? unclear | Mechanistic | DGIdb | |
| K-252A | ? unclear | Mechanistic | DGIdb | |
| ANTIHYPERTENSIVE AGENT | ? unclear | Mechanistic | DGIdb | |
| ENDOTHELIN RECEPTOR ANTAGONIST | ? unclear | Mechanistic | DGIdb | |
| ROSIGLITAZONE | ? unclear | Mechanistic | DGIdb | |
| ESTRADIOL 3-BENZOATE | ? unclear | Mechanistic | DGIdb | |
| BROMOCRIPTINE | ? unclear | Mechanistic | DGIdb | |
| FREUND'S ADJUVANT | ? unclear | Mechanistic | DGIdb | |
| VACCINE | ? unclear | Mechanistic | DGIdb | |
| IMMUNOTOXIN | ? unclear | Mechanistic | DGIdb | |
| ETHER | ? unclear | Mechanistic | DGIdb |
POMC
UCP1
Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.
The aim of this cohort is to evaluate the follow-up of morbidly obese patients treated by several types of bariatric procedures. In addition, this study could lead to the development of clinical trials on assessment of the bariatric surgery impact.
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in Type 2 diabetes mellitus (T2DM) in moderately obese patients. T2DM is ...
In this research, we hypothesize that post-operative monitoring implemented with a connected scale after the 1st year (weight nadir period) post obesity surgery (i.e. sleeve and RYGB) would reduce the percentage of patients with excessive weight regain (\>10% regain of lost weight) by improving the ...
This randomized controlled trial evaluates the efficacy, safety, metabolic, and cardiovascular effects of liraglutide in children aged 6 to 12 years with severe obesity. Participants are randomized to receive liraglutide plus lifestyle intervention or lifestyle intervention alone for 6 months. In ad...
This randomized controlled trial evaluates the effectiveness of adding TECAR therapy or extracorporeal shock wave therapy (ESWT) to complex decongestive therapy (CDT) in the treatment of bilateral lower-limb lymphedema in severely obese patients. Forty-five female participants were randomly assigned...
This study is researching an experimental drug called mibavademab. The study is focused on participants with GLD who have been on metreleptin treatment for at least 6 months with no change in dose for the last 3 months. The aim of the study is to see how safe and tolerable mibavademab is when switc...
Obesity prevalence rapidly increased in the past decades in French population with multiple health consequences responsible for excess mortality. In the same period of time, the number of bariatric procedures have developed exponentially. Despite its great efficacy on weight loss but also on resolut...
The effectiveness of low-protein diets supplemented with essential aminoacid (EAA) formulas in genetic disorders of amino acid (AA) catabolism, such as maple syrup urine disease (MSUD), is widely recognized (Blackburn PR et al. 2017). The main aim of the present study is to evaluate a difference in ...
Obesity is a major public health problem worldwide. Bariatric surgery has proved to be the most effective treatment of morbid obesity in terms of weight reduction and remission of co-morbid conditions during long-term follow-up. Sleeve Gastrectomy (SG) has become the most performed intervention eith...
In the United States, a body mass index (BMI) of at least 35.0 kg/m2 affects about 15% of women of reproductive age. Severe obesity is a significant predictor of adverse perinatal outcomes including gestational diabetes mellitus, pre-eclampsia, premature birth, and at its most severe, fetal death, b...
Obesity is a multifactorial disease which has become a public health problem with increasing frequency, especially in recent years. Obesity causes many health problems with its negative effects on organs, systems, and psychosocial status. It is a serious risk factor for many diseases and also causes...
Obesity is a major global health concern with a rising prevalence and numerous associated comorbidities. For the treatment of severe obesity, bariatric surgery stands as the most effective procedure. Bariatric and metabolic surgical procedures are applied even in the absence of comorbidities, partic...
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver. C...
The main questions to answer are: * Weight outcomes in weight strata over time? * What was the proportion of patients reaching sufficient weight outcome in different weight strata? * To what extent are co-morbid conditions improved or put in remission? * What is the risk of experience a complicatio...
Morbid or severe obesity is a chronic pathology of multifactorial etiology that affects 4.3% of the French population. In these patients, eating disorders are frequent and must be managed as they are considered risk factors with poorer weight prognosis and lower quality of life. Some authors have p...
Searched directly from “Obesity (Severe / Morbid)” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 8-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."